Small Cell Lung Cancer Extensive Stage Clinical Trials

42 clinical trials for Small Cell Lung Cancer Extensive Stage across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer — RECRUITING · PHASE1
• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) — RECRUITING · PHASE1
• Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC — RECRUITING · PHASE1
• The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer — RECRUITING · NA
• Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients — RECRUITING · PHASE1
• Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) — RECRUITING · PHASE2
• Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) — RECRUITING · PHASE1
• A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — RECRUITING · PHASE3
• PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer — RECRUITING · PHASE2
• IN10018 Combination Therapy in Treatment-naïve ES-SCLC — RECRUITING · PHASE1
• First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC — RECRUITING · PHASE2
• Liposomal Irinotecan and Apatinib in ES-SCLC — RECRUITING · PHASE2
• Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC — RECRUITING · PHASE2
• Molecular Analysis and Treatment Options of SCLC — RECRUITING
• Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer — TERMINATED · PHASE2
• BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) — NOT_YET_RECRUITING · PHASE3
• Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) — TERMINATED · PHASE1
• Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer — TERMINATED · PHASE3
• A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059) — NOT_YET_RECRUITING
• Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy — NOT_YET_RECRUITING · PHASE2
• Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer. — NOT_YET_RECRUITING · PHASE2
• Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial — NOT_YET_RECRUITING
• Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease — COMPLETED · PHASE2
• A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer — NOT_YET_RECRUITING · PHASE2
• Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer — NOT_YET_RECRUITING · PHASE2
• Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy — OTHER · PHASE1
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer — OTHER · NA
• KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer — TERMINATED · PHASE2
• Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients — NOT_YET_RECRUITING
• A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC — OTHER · PHASE2
• Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer — COMPLETED · PHASE1
• Immunotherapy as Second-line in Patient With Small Cell Lung Cancer — COMPLETED · PHASE2
• A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） — OTHER · PHASE1
• Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer — OTHER · PHASE2
• Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC — OTHER · PHASE2
• SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer — OTHER · PHASE2
• Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer — TERMINATED · PHASE2
• Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) — OTHER · PHASE2

Refine this search